RxDoctor Payments DataLook up a doctor →

Sanjiv Modi, MD

Hematology & Oncology · Michigan City, INNPI 1396730909

Payments from drug & device makers

$77,268in general payments, 2019–2025

Across 372 payments — averaging $207.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$54K
  • Johnson & Johnson$15K
  • Jazz Pharmaceuticals Inc.$3K
  • Beigene, Ltd.$450
  • Merck$425
  • E.r. Squibb & Sons, L.L.C.$387
  • plus $5K from 53 others

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.19$53,778
Johnson & Johnson(2 entities)68$15,169
Jazz Pharmaceuticals Inc.12$2,532
Beigene, Ltd.1$450
Merck23$425
E.r. Squibb & Sons, L.L.C.23$387
AstraZeneca(2 entities)19$378
Genentech USA, Inc.15$305
Pfizer14$302
Lilly USA, LLC15$267
Novartis14$245
Karyopharm Therapeutics Inc.10$216
Pharmacyclics LLC, An Abbvie Company10$215
Amgen9$187
Eisai Inc.9$169
Sanofi7$162
Incyte Corporation9$162
Global Blood Therapeutics, Inc.6$141
EMD Serono, Inc.6$136
Bristol Myers Squibb8$136
Exelixis Inc.3$111
Seagen Inc.5$107
GSK5$98
Takeda Pharmaceuticals U.S.A., Inc.4$95
Beone Medicines USA, Inc.2$85
Bayer5$84
Gilead(2 entities)5$72
Rigel Pharmaceuticals, Inc.3$69
Astellas Pharma US Inc3$57
Verastem, Inc.2$51
Myovant Sciences Inc.3$49
Taiho Oncology, Inc.3$45
Beigene USA, Inc.2$37
Puma Biotechnology, Inc.2$34
Advanced Accelerator Applications2$33
Myriad Genetic Laboratories, Inc.2$32
AVEO Pharmaceuticals, Inc.2$31
Coherus Oncology, Inc.1$29
Ipsen Biopharmaceuticals, Inc1$28
Regeneron Healthcare Solutions, Inc.1$28
Morphosys, US Inc.1$25
Epizyme, Inc.1$23
ADC Therapeutics America, Inc.1$23
Fresenius Kabi USA, LLC1$22
Medtronic1$21
Telix Pharmaceuticals1$21
AbbVie1$19
Clovis Oncology, Inc.1$19
Array Biopharma Inc1$18
Dendreon Pharmaceuticals LLC1$17
Verity Pharmaceuticals Inc.1$16
EUSA Pharma (US) LLC1$15
Tersera Therapeutics LLC1$15
Acceleron Pharma, Inc.1$14
Deciphera Pharmaceuticals Inc.1$14
Legend Biotech USA Inc.1$13
Adaptive Biotechnologies Corporation1$13
Foundation Medicine, Inc.1$12
Helsinn Therapeutics (U.S.), Inc.1$11

How this compares

$77,268 in reported general payments places this provider in the 75th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana →

Medicare billing

Part B allowed, 2024
$40,147
Medicare patients
65
Services billed
2,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Michigan City

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →